EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
125
Gillespie, Ulrika
ACPE UAN: 0475-0000-19-023-L01-P. A knowledge based activity.
Linked to EAHP Statements
Section 1 – Introductory Statements and Governance: Statements 1.1, 1.2, 1.3, 1.4, 1.6
Section 4 – Clinical Pharmacy Services: Statements 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8
Section 5 – Patient Safety and Quality Assurance: Statements 5.1, 5.2, 5.4, 5.5, 5.6, 5.8, 5.9, 5.11
Section 6 – Education and Research: Statements 6.2, 6.5
Abstract
Pharmacogenomics is the study and clinical application of the genetic determinants of drug response. Pharmacogenomics represents one of the cornerstones of personalised medicine in which drugs and drug combinations can be expected to be tailored to a patient’s unique genetic profile.
The availability of genomic testing is growing, and patients may present today with genetic profiles that they have acquired in various ways. Information from genomic testing may be used in clinical practice to inform drug and dose selection to improve treatment efficacy, reduce adverse drug effects, reduce polypharmacy, and eventually improve clinical outcomes.
Over 200 US Food and Drug Administration (FDA)-approved drugs now contain pharmacogenomic information within their product label. Importantly, clinical guidelines providing therapeutic recommendations for over 40 well-known gene-drug pairs have now been produced by the US Clinical Pharmacogenetics Implementation Consortium (CPIC) and/or Dutch Pharmacogenetics Working Group (DPWG). In Europe, the Ubiquitous Pharmacogenomics (U-PGx) international consortium is conducting the PREPARE implementation multicenter prospective study to assess the clinical utility of pre-emptive genotyping to optimise the prescribing for multiple drugs across a range of therapeutic areas based on the DPWG recommendations.
In Ontario, Canada, the PRIME study (http://www.open-pharmacy-research.ca/research-projects/prime/) is ongoing, where pharmacists receive a training package on pharmacogenomics and its applied use, with the focus on psychiatric medications. The pharmacists then work in multi-disciplinary teams, using genomic information to find the best medication options for the patients.
This interactive session will demonstrate how the growing science of pharmacogenomics can be brought to clinical practice. What knowledge and skills are needed by the clinicians? What are the opportunities and limitations within this field?
Learning objectives
After the interactive session, participants should be able to:
• describe how prescribing may be tailored by pharmacogenomics – today and in the future;
• outline the role of pharmacists in the clinical application of pharmacogenomics;
• describe how a medication review is performed in the PRIME study, using pharmacogenomic information.
Educational need addressed
Using information from genomic testing when performing medication reviews is not yet common practice, although it is often used for deciding the optimal treatment alternative in, for example, cancer patients. There is an increasing awareness among pharmacists that this is a field they need to familiarise themselves with.
Keywords | Pharmacogenomics, genomic testing.
